Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
22/12/202209:29PR Newswire (US)Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of MedicineNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/12/202209:45Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
21/12/202208:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
21/12/202208:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
21/12/202208:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
21/12/202208:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
21/12/202208:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
20/12/202208:01PR Newswire (US)Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:REGNRegeneron Pharmaceuticals Inc
17/12/202200:23Dow Jones NewsRegeneron, Sanofi Get CHMP Backing for Dupixent in Eosinophilic EsophagitisNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/12/202223:29PR Newswire (US)Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic EsophagitisNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/12/202216:59PR Newswire (US)Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo NodularisNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/12/202208:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
14/12/202208:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
14/12/202208:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
14/12/202208:12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
14/12/202208:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
14/12/202208:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202209:30PR Newswire (US)Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 TrialNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202208:36Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202208:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202202:00PR Newswire (US)Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/12/202223:30PR Newswire (US)Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive YearNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/12/202202:30PR Newswire (US)Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASHNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/12/202215:30TipRanksAnalysts Offer Insights on Healthcare Companies: Regeneron (REGN), Ascendis Pharma (ASND) and Beam Therapeutics (BEAM)NASDAQ:REGNRegeneron Pharmaceuticals Inc
03/12/202208:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
03/12/202208:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
03/12/202208:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
01/12/202223:00PR Newswire (US)Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor TypesNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/12/202200:05PR Newswire (US)Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority ReviewNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/11/202205:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN